Quality of life in patients with atopic dermatitis: Impact of tacrolimus ointment

International Journal of Dermatology

Volumn 45, Issue 6, 2006, Pages 731-736

  Kawashima, Makoto ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JAPAN; MALE; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SKIN MANIFESTATION; WORLD HEALTH ORGANIZATION;

ATTITUDE TO HEALTH; DERMATITIS, ATOPIC; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; QUALITY OF LIFE; QUESTIONNAIRES; SAFETY; SOCIAL BEHAVIOR; TACROLIMUS; TOKYO; WORLD HEALTH ORGANIZATION;

EID: 33744925521     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02705.x     Document Type: Article

References (24)

1. Taieb A. The natural history of atopic dermatitis. J Am Acad Dermatol 2001; 45: S4-S6.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118-S127.
3. Ahuja A, Land K, Barnes CJ. Atopic dermatitis. South Med J 2003; 96: 1068-1072.
4. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003; 112: S140-S150.
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
6. Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-517.
7. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28: 551-558.
8. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158.
9. Russell JJ. Topical tacrolimus: A new therapy for atopic dermatitis. Am Fam Physician 2002; 66: 1899-1902.
10. Lazarus MC, Kerdel FA. Topical tacrolimus Protopic (R). Drugs Today (Barc) 2002; 38: 7-15.
11. Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2: 389-406.
12. Gianni LM, Sulli MM. Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother 2001; 35: 943-946.
13. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.
14. The Japanese FK506 ointment Study Group. Long-term study: FK506 (tacrolimus) ointment in patients with atopic dermatitis - analysis at the time completion of 2-year observation. Rinshouiyaku 2001: 705-726.
15. Hisatomi A, Mitamura T, Kimura M, et al. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal atrophogenicity in rats. J Toxicol Pathol 1997; 10: 97-102.
16. Tazaki Y, Nakane Y. Manual of WHOQOL-26. Tokyo: Kanekoshobo, 1997.
17. Nakane Y, Tazaki M, Miyaoka E. WHOQOL-BREF survey of general population. Iryo Shakai 1999; 9: 7-15.
18. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13-14.
19. Yoshihara N. Evaluation of admission treatment based on topical steroid therapy for atopic dermatitis patients using visual analogue scale. Nippon Hifuka Gakkai Zasshi 1999; 109: 1173-1178.
20. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life. Pharmacoeconomics 2003; 21: 159-179.
21. Takehara K. Cautious point in the treatment of atopic dermatitis. Steroid refusal. Arerugi No Rinsho 2000; 20: 42-47.
22. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-S72.
23. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-972.
24. Barbier N, Paul C, Luger T, et al. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96-102.